Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas

[1]  Raymond Y Huang,et al.  Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. , 2020, Neuro-oncology.

[2]  Sankha S. Basu,et al.  Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Roberts,et al.  Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Lewis C. Cantley,et al.  The PI3K Pathway in Human Disease , 2017, Cell.

[5]  G. Adelmant,et al.  CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. , 2017, Cell reports.

[6]  L. Cantley,et al.  PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α , 2017, Proceedings of the National Academy of Sciences.

[7]  T. Roberts,et al.  Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss , 2016, eLife.

[8]  E. Chiocca,et al.  BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma , 2016, Scientific Reports.

[9]  T. Roberts,et al.  A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis , 2015, Nature Communications.

[10]  J. Engelman,et al.  Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. , 2015, Cancer cell.

[11]  Jean J. Zhao,et al.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting , 2014, Nature Reviews Cancer.

[12]  T. Roberts,et al.  The Phosphatidylinositol 3-Kinase (PI3K) Isoform Dependence of Tumor Formation Is Determined by the Genetic Mode of PI3K Pathway Activation Rather than by Tissue Type , 2014, Journal of Virology.

[13]  Susan M. Chang,et al.  Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma. , 2014 .

[14]  T. Roberts,et al.  PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context , 2014, Proceedings of the National Academy of Sciences.

[15]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[16]  R. Bronson,et al.  Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. , 2013, Genes & development.

[17]  G. Stamp,et al.  RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms , 2013, Cell.

[18]  Hailing Cheng,et al.  The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. , 2012, Genes & development.

[19]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[20]  W. Sellers,et al.  Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations , 2012, Molecular Cancer Therapeutics.

[21]  W. Mason,et al.  Phase II study of PX-866 in recurrent glioblastoma. , 2012, Neuro-oncology.

[22]  N. Gray,et al.  Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. , 2012, Cancer discovery.

[23]  Gerald J. Sun,et al.  In Vivo Clonal Analysis Reveals Self-Renewing and Multipotent Adult Neural Stem Cell Characteristics , 2011, Cell.

[24]  G. Ming,et al.  Adult Neurogenesis in the Mammalian Brain: Significant Answers and Significant Questions , 2011, Neuron.

[25]  Gerald C. Chu,et al.  P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation , 2008, Nature.

[26]  P. Musiani,et al.  Phosphoinositide 3-Kinase p110β Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development , 2008, Science Signaling.

[27]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[28]  M. Loda,et al.  Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis , 2008, Nature.

[29]  Hailing Cheng,et al.  The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation , 2006, Proceedings of the National Academy of Sciences.

[30]  K. Okkenhaug,et al.  Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation , 2006, Nature.

[31]  R. Nussbaum,et al.  Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase , 2002, Mammalian Genome.

[32]  R. Nussbaum,et al.  Proliferative Defect and Embryonic Lethality in Mice Homozygous for a Deletion in the p110α Subunit of Phosphoinositide 3-Kinase* , 1999, The Journal of Biological Chemistry.

[33]  W. Hahn,et al.  Tyrosine receptor kinase B is a drug target in astrocytomas , 2017, Neuro-oncology.

[34]  Brent A Reynolds,et al.  Neural stem cell isolation and characterization. , 2006, Methods in enzymology.